• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sucampo Pharmaceuticals - Articles and news items

FDA grants fast track designation to Sucampo’s cobiprostone for oral mucositis

Industry news / 8 May 2015 / Victoria White

The FDA has granted Fast Track Designation for cobiprostone, a locally acting chloride channel activator, for the prevention of oral mucositis.

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringFIND OUT MORE
+ +